Among them, CCR8+Tregs are recognized as a prototypical highly suppressive subset, whose dense infiltration within the TME markedly limits the therapeutic efficacy of αPD-1 antibodies in NSCLC (47). This evidence concerns the gene CCR8 and non-small cell lung carcinoma.